Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part II) [Эффективность и безопасность тофацитиниба при...

Насонов Е. Л., Авдеева А. С., Лила А. М.
Научно-практическая ревматология
Т. 58, Вып. 2, С. 214-224
Опубликовано: 2020
Тип ресурса: Обзор

DOI:10.14412/1995-4484-2020-214-224

Аннотация:
The design of targeted oral anti-inflammatory drugs, such as Janus kinase (JAK) inhibitors, the first representative of which is tofacitinib (TOFA), is considered a major achievement in biology and medicine early in the 21st century. Part I of the review considers the materials of studies evaluating the efficacy and safety of TOFA in rheumatoid arthritis (RA). The expansion of ideas about the mechanisms of development and chronicity of inflammation and the anti-inflammatory and immunomodulatory effects of TOFA using a RA model has created theoretical and clinical prerequisites for studying the efficacy of TOFA in other immune-mediated inflammatory rheumatic diseases (IMIRDs) and chronic inflammatory non-rheumatic diseases. Part II of the review summarizes new data that allow one to formulate main areas of further clinical and fundamental studies, the objective of which is to expand indications for and to personalize therapy with JAK inhibitors in patients with IMIRDs. © 2020 Ima-Press
Ключевые слова:
Immune-mediated inflammatory rheumatic diseases; JAK inhibitors; Tofacitinib
tofacitinib; antiinflammatory activity; chronicity; drug effect; drug efficacy; drug indication; drug safety; human; immunomodulation; inflammation; personalized medicine; Review; rheumatoid arthritis
Язык текста: Русский
ISSN: 1995-4492
Насонов Е. Л. Евгений Львович 1948-
Авдеева А. С.
Лила А. М.
Nasonov E. L. Evgenij L`vovich 1948-
Avdeeva A. S.
Lila A. M.
Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part II) [Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть II)]
Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part II) [Эффективность и безопасность тофацитиниба при...
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 58, Вып. 2 С. 214-224
2020
Обзор
Immune-mediated inflammatory rheumatic diseases JAK inhibitors Tofacitinib
tofacitinib antiinflammatory activity chronicity drug effect drug efficacy drug indication drug safety human immunomodulation inflammation personalized medicine Review rheumatoid arthritis
The design of targeted oral anti-inflammatory drugs, such as Janus kinase (JAK) inhibitors, the first representative of which is tofacitinib (TOFA), is considered a major achievement in biology and medicine early in the 21st century. Part I of the review considers the materials of studies evaluating the efficacy and safety of TOFA in rheumatoid arthritis (RA). The expansion of ideas about the mechanisms of development and chronicity of inflammation and the anti-inflammatory and immunomodulatory effects of TOFA using a RA model has created theoretical and clinical prerequisites for studying the efficacy of TOFA in other immune-mediated inflammatory rheumatic diseases (IMIRDs) and chronic inflammatory non-rheumatic diseases. Part II of the review summarizes new data that allow one to formulate main areas of further clinical and fundamental studies, the objective of which is to expand indications for and to personalize therapy with JAK inhibitors in patients with IMIRDs. © 2020 Ima-Press